Home›Research›Compare›NAD+ vs Teriparatide
Peptide ComparisonNAD+ vs Teriparatide
Both are Longevity & Cellular peptides.
NAD+
NAD
Half-life: ~1–2 hours (IV); variable (oral)
451 providers listed
Teriparatide
Forteo
Half-life: ~1 hour
3 providers listed
Teriparatide is FDA-approved, while NAD+ is evaluated not recommended — the clearest structural difference between them.
NAD+
Half-life
~1–2 hours (IV); variable (oral)
Teriparatide
Half-life
~1 hour
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Teriparatide |
| Further along in FDA review | Teriparatide |
| Oral administration option | NAD+ |
| More provider options (451 vs 3) | NAD+ |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
NAD+
Teriparatide
NAD+
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and…
Mitochondrial quality control in human ageing and longevity.
Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
Teriparatide
The impact of parathyroid hormone supplementation on dental implant osseointegration in osteoporotic subjects…
Pharmacological Management of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living…
Association between antiosteoporosis medications and risk of sacral fracture after lumbosacral fusion in adul…
Biological Augmentation of Reamed Intramedullary Nailing for Aseptic Tibial Shaft Nonunion: An Exploratory Mu…
About NAD+
NAD+ is a coenzyme central to cellular energy metabolism, serving as an electron carrier in glycolysis, the citric acid cycle, and oxidative phosphorylation. It is also a required substrate for sirtuins (SIRT1–7) and PARP enzymes, which regulate DNA repair, gene expression, and mitochondrial biogenesis. NAD+ levels decline measurably with age; IV or subcutaneous delivery aims to restore intracellular pools more directly than oral precursors such as NMN or NR.
About Teriparatide
Recombinant PTH 1-34; when given intermittently, preferentially activates osteoblasts over osteoclasts; increases bone remodeling and net bone formation; stimulates IGF-1 in bone
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
NAD+
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Teriparatide
No established clinical contraindications
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
NAD+
Teriparatide
Not enough vendor pricing yet.
Where to source these peptides
NAD+
451 listed
Browse directory →
Providers offeringTeriparatide
3 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Longevity & Cellular Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). NAD+ vs Teriparatide — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/nad-plus/teriparatide